Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosi...

Por Chen, Qi, Quan, Qi, Ding, Lingyu, Hong, Xiangchan, Zhou, Ningning, Liang, Ying, Wu, Haiying
Publicado no Oncotarget (2015)

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer

Por Hong, Xiangchan, Chen, Qi, Ding, Lingyu, Liang, Ying, Zhou, Ningning, Fang, Wenfeng, Chen, Xinru, Wu, Haiying
Publicado no Oncotarget (2017)

Effects of cancer-testis antigen, TFDP3, on cell cycle regulation and its mechanism in L-02 and HepG2 cell lines in vitro

Por Jiao, Yunshen, Ding, Lingyu, Chu, Ming, Wang, Tieshan, Kang, Jiarui, Zhao, Xiaofan, Li, Huanhuan, Chen, Xi, Gao, Zirui, Gao, Likai, Wang, Yuedan
Publicado no PLoS One (2017)

Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy

Por Xie, Congying, Yang, Pengfei, Zhang, Xuebang, Xu, Lei, Wang, Xiaoju, Li, Xiadong, Zhang, Luhan, Xie, Ruifei, Yang, Ling, Jing, Zhao, Zhang, Hongfang, Ding, Lingyu, Kuang, Yu, Niu, Tianye, Wu, Shixiu
Publicado no EBioMedicine (2019)

Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial

Por Luo, Honglei, Jiang, Wei, Ma, Li, Chen, Peng, Fang, Min, Ding, Lingyu, Hua, Yuhui, Du, Dexi, Jing, Zhao, Xie, Ruifei, Song, Yaqi, Wang, Jiayang, Zhou, Rongjing, Tian, Zhifeng, Wu, Shixiu
Publicado no JAMA Netw Open (2020)

Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial

Por Xie, Congying, Jing, Zhao, Luo, Honglei, Jiang, Wei, Ma, Li, Hu, Wei, Zheng, Anping, Li, Duojie, Ding, Lingyu, Zhang, Hongyan, Xie, Conghua, Lian, Xilong, Du, Dexi, Chen, Ming, Bian, Xiuhua, Tan, Bangxian, Xia, Bing, Xie, Ruifei, Liu, Qing, Wang, Lvhua, Wu, Shixiu
Publicado no Br J Cancer (2020)